Early mortality in multiple myeloma: the time‐dependent impact of comorbidity: A population‐based study in 621 real‐life patients

Abstract

Multiple myeloma is a heterogeneous disease with variable survival; this variability cannot be fully explained by the current systems of risk stratification. Early mortality remains a serious obstacle to further improve the trend toward increased survival demonstrated in recent years. However, the definition of early mortality is not standardized yet. Importantly, no study has focused on the impact of comorbidity on early mortality in multiple myeloma to date. Therefore, we analyzed the role of baseline comorbidity in a large populationbased cohort of 621 real-life myeloma patients over a 31-year period. To evaluate early mortality, a sequential multivariate regression model at 2, 6, and 12 months from diagnosis was performed. It was demonstrated that comorbidity had an independent impact on early mortality, which is differential and time-dependent. Besides renal failure, respiratory disease at 2 months, liver disease at 6 months, and hepatitis virus C infection at 12 months, were, respectively, associated with early mortality, adjusting for other well-established prognostic factors. On the other hand, the long-term monitoring in our study points out a modest downward trend in early mortality over time. This is the first single institution population-based study aiming to assess the impact of comorbidity on early mortality in multiple myeloma. It is suggested that early mortality should be analyzed at three key time points (2, 6, and 12 months), in order to allow comparisons between studies. Comorbidity plays a critical role in the outcome of myeloma patients in terms of early mortality.Am. J. Hematol. 91:700-704,

Current Review on High-Risk Multiple Myeloma

“…In one of the analyses done by IMWG mentioned above, renal impairment was noted to be an independent risk factor for survival [33], and this was also confirmed by a populationbased study from Spain [34]. However, recent data indicate that bortezomib-based treatment can potentially overcome the adverse effect of renal impairment [35,36].…”

Understanding mortality in multiple myeloma: Findings of a European retrospective chart review

“…17 Comorbidities were found to have an independent impact on early mortality: at different time points, renal failure, respiratory disease, liver disease and hepatitis C infection were each associated with early mortality. 17 Similarly, a large chart review across seven European countries found that comorbidities reduced continuation to the next treatment line. 12 These studies suggest that disease-related prognostic variables, such as ISS stage and cytogenetic risk, 18 are not the only determinants of death early in the disease course.…”

Infectious complications in patients with multiple myeloma on first chemotherapy cycle

“…Частота инфекционных осложнений у больных ММ существенно ниже в сравнении с больными острымилейкозамиисоставляет6,8%против68,4% соответственно. В то же время именно инфекции являются одной из основных причин летальности, особеннонараннихэтапахлеченияММ [12].Летальныеисходы,регистрируемыевтечение1-гогодале-ченияММ,составляютот6до31,7 %иобусловлены прежде всего инфекционными осложнениями [13]. Так,висследованииB.…”